WEBINARS AND VIDEOS

6:52

CMC Considerations Around Unique Materials And Reagents

15:16

The CDMO's Perspective: Audience Q&A With Thermo Fisher Scientific

14:37

How Raw Material Decisions Can Impact Process Performance

12:49

Transitioning A Process And Qualifying GMP Materials

10:39

Demonstrating GMP Readiness And Understanding Common Pain Points

27:56

Accelerating CHO Media Development: From Screening To AI Design

28:50

Evaluating Modular CAR T Manufacturing Workflows

58:02

Driving Productivity Across The Antibody Manufacturing Workflow

33:40

De-Risking Cell Culture Media Scale-Up For Late-Stage Manufacturing

40:32

Driving Measurable Productivity Gains In CHO Cell Culture

54:11

The Future Of Cell Culture Media Development

44:28

From Data To Decisions: AI And Multi-Omics For Cell Culture Development

• How Modular Workflows Are Redefining CAR T Manufacturing

  Learn how flexible modular workflows can help manufacturers improve process adaptability, throughput, and control while preserving key CAR T quality attributes, including transduction efficiency.

• Reducing Particulate-Related Batch Risk In Bioprocessing

  Increasing scrutiny around particulate contamination is pushing teams to act earlier. Understanding where risks originate and applying proactive strategies can ease challenges across production.

• Choosing The Right Metrics To Measure Process Performance

  In this opening segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), discuss what metrics matter the most to evaluate productivity and measure process performance.

• Using Better Tools And Better Data To Drive Process Productivity

  In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” our panelists respond to an audience poll and answer audience questions about hollow fiber membranes and process modeling approaches. They agree that productivity gains emerge from a comprehensive understanding of the process and the tools that enable it.

• Simplifying Downstream Unit Operations To Increase Productivity

  In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), discuss the biggest opportunity to improve process yield and performance: reducing chromatography steps and unlocking efficiencies downstream.

• Upstream Decisions Influence Downstream Challenges

  In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), answer the question, “What should developers be thinking about upstream to avoid downstream complications?” Klyushnichenko believes process-wide considerations like this begin earlier than cell line development at the product’s molecular construct itself.

• Understanding Fixed Variables And Working Within Their Constraints

  Some things are intrinsic, unchanging realities of a process — molecular complexity, product developability, and facility fit, to name a few. In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), discuss these “non-pullable levers” of process development and advise teams on how to work within their boundaries.

• Next-Generation Molecules Challenge Notions Of Yield And Performance

  In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), discuss how the process-related associated with next-generation molecules like bispecifics and trispecifics complicate downstream purification efforts impurities (e.g., chain mispairings). They agree that mitigating these impurities is a developmental challenge both upstream and downstream.

• Productivity Gains Upstream Apply Pressure Downstream

  In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), reflect on the progress that’s been made in terms of productivity gains and the “ceiling” that mAbs face, and how these upstream gains stress downstream operations. They also discuss how molecular complexity relates to challenges in purification.

• Continuous Manufacturing As A Powerful Productivity Lever

  In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), discuss the potential of perfusion and continuous manufacturing to improve productivity through smaller facility footprints and greater output over time. They also examine the challenges associated with these approaches, including cell-line stability, process monitoring, and the cost of operational mistakes.

• How Intensified Upstream Processing Improves Scale-Up And Tech Transfer

  Intensified upstream processing can improve scalability and maintain quality. Learn how automation, PAT, and data-driven control strategies help modernize workflows and support consistent performance.

• Generate Stable High-Producing Clones In 14 Weeks

  Rising complexity is putting pressure on cell line development. Discover a streamlined approach that enables rapid generation of stable clones with strong titers and long-term consistency.

• Using Residual DNA Quantification Data To De-Risk mAb Development

  Residual DNA quantitation offers more than impurity measurement. When used across process steps, it helps compare purification performance, identify risks early, and ensure assays remain reliable.

• Efficient mAb Development With A Flexible Purification Toolkit

  Increasing mAb complexity is pushing purification beyond traditional platforms. See how flexible chromatography, optimized buffers, and adaptable workflows are becoming essential to achieve target purity.

• CAR-T Strategy In 2026: Scaling Autologous, Advancing Allogeneic

  As CAR-T advances, shifting clinical progress and market dynamics are reshaping development strategies. Explore how evolving therapies and operational demands are redefining the next wave of innovation.

• Maximizing Performance And Quality In Fed-Batch And Perfusion-Based IgG Productions Customer Interview

  From lab to production scale: a researcher's firsthand account of what bioreactor scaling and high-density perfusion really demand in practice.

• How MacroGenics Increased mAb Titers By Up To 80% In Scale-Up

  Learn how a structured, scalable approach to process development can help improve productivity, maintain product quality, and support a smoother transition to manufacturing.

• Boost CHO Cell Protein Production By Up To 146% With Efficient-Pro™ Feed Solutions

  Up to 146% higher protein titers in CHO-K1 culture. See how advanced feed technology and animal–origin–free formulations are redefining what consistent protein production looks like.

• Driven By Performance: Empowering Biotech Innovation From Lab To Life

  See how the right biotech products, workflows, and technical expertise help teams accelerate development and bring life-changing therapies from lab to commercial reality.

• Defined Media, Defined Results: Scaling E. coli From Bench To Fermenter

  Understand the benefits of chemically defined media in E. coli systems, explore real-world plasmid DNA data, and learn practical strategies for scaling to robust manufacturing.

• DynaDrive S.U.B. Video Series

  Explore DynaDrive Single-Use Bioreactors through expert videos covering reactor design, mixing performance, sparge technology, and scalable workflows from bench-scale to commercial production.

• Digital Design Meets Proven Performance: The Future Of Single-Use Assemblies

  Single-use assembly design is evolving fast. Learn how scalable platforms, digital automation tools, and global supply networks are converging to support sustainable biopharma manufacturing at scale.

• DynaDrive Single-Use Bioreactors Drilled-Hole Sparge Technology

  Uniform bubble size and consistent mass transfer across scales through drilled-hole sparge technology improves oxygen delivery and CO2 stripping in demanding cell culture processes.

• DynaDrive Single-Use Bioreactors - One Reactor, Many Volumes

  Single-use bioreactors with turndown ratios up to 20:1 enable facilities to operate across wide volume ranges within the same vessel, streamlining seed trains and reducing capital requirements for multi-product operations.

• Scale With Confidence From Bench To Commercial Production

  Consistent vessel design, sparging, and bag materials across 1L to 5,000L volumes enable predictable bioreactor scale-up from development through commercial manufacturing.

• Why Is The Bioreactor Square? The Geometry Behind Exceptional Mixing

  Cuboid bioreactor design eliminates vortexing through natural baffling, delivering homogeneous mixing and consistent nutrient distribution for high cell density upstream processes.

• Aegis Film For DynaDrive Single-Use Bioreactors

  PFAS-free bioreactor film technology provides proven biocompatibility and strength across workflows while simplifying validation and reducing material variability for compliant operations.

• Applying AI And Rapid Prototyping To Media And Process Development

  Hear from industry experts on how teams can integrate manufacturability considerations earlier through rapid prototyping, data-driven media development, and predictive modeling.

• Five Reasons To Choose Single-Use Bioreactors

  Explore five key advantages of single-use bioreactors, including scalable design, homogeneous mixing, broad chemical compatibility, and streamlined seed train processes for bioproduction success.

• Go Beyond Custom Media Screening And Prototyping

  Learn about manufacturing solutions that streamline cell culture media scale-up with global production capabilities, equivalency strategies, and quality assurance for reliable supply.

• Take The Lead With The Gibco CHOvantage™ GS Cell Line Development Kit

  See how this kit accelerates clone development to 14 weeks with ≥7 g/L protein titers while reducing costs through royalty-free commercial licensing for therapeutic applications.

• Protecting Biopharma Manufacturing Supply Chains

  In this final segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists Adam Golin, Jon Lindbloom, and James Sapirstein share their advice and best practices for sourcing suppliers and staying agile during periods of change in the industry.

• Building Resilience In Biomanufacturing Operations

  In this segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists share their thoughts on what it means to be resilient and how organizations can embody resilience in their biomanufacturing, which in part requires agility and preparation for the worst-case scenario. The panel was in agreement that earlier-phase companies have the highest opportunity to bake resilience into their operations.

• How Will U.S. Tariffs And The BIOSECURE Act Impact Global Biopharma Markets?

  In this segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists explain how tariffs imposed by the U.S. are putting competitive pressure on companies to reduce COGs. They also discuss the short- to long-term impact of efforts to onshore biomanufacturing.

• Bioprocessing Raw Material And Equipment Costs Are Slow To Recover Post-Pandemic

  In this segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” our panel discusses how the still-high cost of materials and equipment is being factored into manufacturing decisions, as well as how the COVID-19 pandemic changed the way operators think about supply chains.

• How Is U.S. Policy Reshaping Global Biomanufacturing Operations?

  In this opening segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists Adam Golin, Jon Lindbloom, and James Sapirstein speak candidly about how U.S. tariffs are affecting the global operating environment.

• From Lab To Commercialization: Simplifying Bioprocess Scale-Up

  Explore how unique cuboid geometries and advanced mixing dynamics create consistent performance from the bench to commercial manufacturing, ensuring flexibility and improved productivity.

• Unlock Productivity In mAb Production: Upstream And Downstream Intensification

  Boost your mAb manufacturing efficiency by mastering upstream and downstream intensification strategies. Learn how to minimize cost and time while increasing overall productivity.